26 September 2007 23:47 [Source: ICIS news]
HOUSTON (ICIS news)--Sigma-Aldrich Fine Chemicals (SAFC) will invest $29m (€21m) to expand its drug substance capabilities in high-potency biologics at its facility in Jerusalem, Israel, the company said on Wednesday.
The investment will enable SAFC to provide process development and GMP (good manufacturing practices) manufacturing to customers requiring large-scale, high-potency, toxic or hazardous drug substances, the company said.
Scheduled for completion in the first quarter of 2009, the 50,000 square foot high-potency fermentation expansion will focus production on secondary metabolites (antibiotic-like molecules), cytotoxins and large-molecule proteins.
A 30,000 square foot area of the facility has been designed to be Biosafety Level 2 compliant - enabling manipulation of human pathogens. Site capabilities include 1,000 and 4,000-litre tank capacities for bacterial and fungal fermentation.
($1.00 = €0.71)
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections